Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401’s Mechanism of Action

 Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401’s Mechanism of Action

Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401’s Mechanism of Action

Shots:

  • Eisai and BioArctic collaborate to further characterize the MOA of BAN2401. Earlier in 2005, the companies partnered for the therapy targeting Alzheimer’s disease and later in 2007, BioArctic licensed BAN2401 to Eisai
  • Under the research collaboration, BioArctic will receive $3.89M from Eisai and is expected to continue the collaboration through the end of Jun’2021
  • BAN2401 is an investigational mAb selectively targeting toxic amyloid-beta aggregates in the brain, currently being evaluated in P-III CLARITY study in patients with early Alzheimer´s disease with its anticipated results in 2020

Click here ­to­ read full press release/ article | Ref: BioArctic | Image: Eisai

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post